BioCentury
ARTICLE | Clinical News

Medday's MD1003 meets Phase III endpoint in MS

April 18, 2015 12:53 AM UTC

Medday S.A.S. (Paris, France) said MD1003 met the primary endpoint of disease improvement in a Phase III trial to treat progressive multiple sclerosis (MS).

The primary endpoint was defined as the proportion of patients who showed improvement vs. placebo after nine months of daily treatment with 300 mg MD1003, with confirmation of the result at 12 months. Improvement was defined as either a decrease in Expanded Disability Status Scale (EDSS) score of at least 1 point from a baseline EDSS ≤5.5, or a decrease of 0.5 points from a baseline EDSS ≥6; or improvement of at least 20% in a timed 25-foot walk (TW25) test. The study enrolled 154 patients with baseline EDSS scores of 4.5-7. ...